Q2 2026 Earnings Call February 10, 2026 6:00 PM ESTCompany ParticipantsMark DehringGordon NaylorKen Lim - Chief Financial ...

Exclusive licensing grants Lilly development and commercialization rights for clazakizumab beyond ESKD-related cardiovascular prevention, while CSL retains the ESKD cardiovascular events indication.

With pressure piling on for CSL, the Australian vaccine and plasma specialist has elected to part ways with its CEO on the eve of its latest earnings announcement. | Paul McKenzie, Ph.D., who’s served ...

One day after CSL suddenly replaced its CEO, the company provided dismal financial figures that helped explain why. | One day after CSL revealed that it had suddenly replaced its CEO, the company ...

Bell Potter has given its take on this fallen giant. The post Are CSL shares a buy after this week's brutal selloff? appeared ...

A toxic mix of Americans turning away from vaccines, collapsing blood plasma sales in China and a billion-dollar impairment ...

A toxic mix of Americans turning away from vaccines, collapsing blood plasma sales in China and a billion-dollar impairment ...

CSL's underlying earnings fell in the first half, but management stuck to its full-year guidance and boosted the buy-back.

Formerly the Commonwealth Serum Laboratories, CSL grew under McNamee into a world leader in blood fractionation, where plasma ...

CSL reported half-year underlying NPATA of US$1.9 billion, down 7% in constant currency, with reported net profit plunging 81% to US$401 million as government policy changes, restructuring costs and ...

By Roushni Nair and Byron Kaye SYDNEY, Feb 11 (Reuters) - CSL Ltd on Wednesday reported an 81% drop in first‑half profit, knocked by weaker blood plasma product and vaccine sales and one-off charges, ...

Pain related to sickle cell disease (SCD) increases during menstruation, as do emergency department (ED) visits and hospitalizations, for many women and girls — according to a new, nationwide study ...